Hearst Foundation Developmental News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Get latest articles and stories on Health at LatestLY. Dolutegravir is one of the most potent antiviral drugs now being used in clinical practise to treat HIV. Scientists from the Salk Institute and the National Institutes of Health have discovered the molecular routes through which the human immunodeficiency virus (HIV) develops resistance to it. Health News | Study Sheds Light on Molecular Mechanisms of HIV Drug Resistance.

Salk Institute researchers, in collaboration with the National Institutes of Health, have discovered the molecular mechanisms by which the human immunodeficiency virus (HIV) becomes resistant to Dolutegravir, one of the most effective, clinically used antiviral drugs for treating HIV.

Salk Institute researchers, in collaboration with the National Institutes of Health, have discovered the molecular mechanisms by which the human immunodeficiency virus (HIV) becomes resistant to Dolutegravir, one of the most effective, clinically used antiviral drugs for treating HIV. Their findings reveal how changes to the 3D structures of integrase, an HIV protein, can lead to Dolutegravir resistance and how other compounds may be able to overcome this resistance.

Scientists have determined the molecular structure of HIV Pol, a protein that plays a key role in the late stages of HIV replication, or the process through which the virus propagates itself and spreads through the body.

Understanding how HIV replicates within cells is key for developing new therapies that could help nearly 40 million people around the world who are living with HIV, the immune system virus that causes AIDS.